Endocrine Abstracts

BackgroundPatients with acromegaly may have high symptom burden. The phase 3 MPOWERED trial assessed control of acromegaly by oral octreotide capsules (OOC; MYCAPSSA®) in comparison to injectable somatostatin receptor ligands (iSRLs) in patients responding to both OOC and iSRLs. iSRLs have been first-line medical treatment for patients with acromegaly for decades. OOC are newly approved in the US for patients previously controlled on iSRL...

Adult growth hormone deficiency (GHD), a condition characterized by increased oxidative stress (OS), is related to augmented cardiovascular, metabolic and oncological risk. Thymidine-glycol (ThyG) (5, 6-dihydro-5, 6-dihydroxy-2’-deoxythymidine) is a marker of DNA oxidation produced when thymidine is damaged by hydroxyl radicals. It is considered a specific marker since it is not incorporated in RNA; while 8-OH-deoxyguanosine, a well-known marker of oxidative damage, is ra...

BackgroundOral octreotide capsules (OOC; MYCAPSSA®) are approved in the US for individuals with acromegaly who responded to and tolerated treatment with injectable somatostatin receptor ligands (iSRLs). Add-on cabergoline therapy has shown effectiveness in patients previously inadequately controlled with iSRLS.1 The phase 3 MPOWERED trial assessed maintenance of response with OOC compared to iSRLs. Patients receiving OOC and in...

Background CPHD is characterized by GH and at least one other pituitary hormone deficiency. Mutations in genes expressed in the developing head, hypothalamus, and/or pituitary cause CPHD. To date around 30 genes have been identified to be related to CPHD, however 85% of the cases remain with unknown molecular aetiology.Patient and methodsA newborn boy (46, XY) delivered by CS due to IUGR with a birthweight of...

IntroductionThe oral 11β-hydroxylase inhibitor, osilodrostat, normalized mean urinary free cortisol (mUFC) in 79% (15/19) of patients with Cushing’s disease at the end of the 22-week core LINC 2 study. Long-term efficacy and safety data following an optional extension phase are reported here.MethodsPatients with clinical benefit at week 22 could continue receiving osilodrostat during the extension; ...

BackgroundData on clinical characteristics and natural history of patients with non-functioning pituitary microadenomas (NFPmA) is limited to small-scale studies.MethodsA retrospective evaluation of initial clinical presentation and natural history of patients with NFPmA (conservatively managed, years; 2004–2020) was undertaken. Initial symptoms, tumor size, and pituitary function were assessed. Exclusio...

BackgroundPituitary disease registries are major instruments of epidemiological and clinical data collection used worldwide.ObjectiveTo assess the data of pituitary tumor registry in Russia.Material and methodsPatient records, retrieved from online platform of the Registry.ResultsCurrently there are 9858 patients regis...

BackgroundOptimal management of patients with neuroendocrine tumours (NETs) is essential to ensure the best treatment results. This survey aimed to obtain a comprehensive picture of NET management in Poland by examining the pathway of patients with NETs throughout their diagnosis and treatment.MethodsPhysicians treating patients with NET in 17 Polish clinical centres/hospital wards, covering approximately 80%...